Castle Biosciences, Inc. (CSTL) has a consensus analyst rating of Buy, based on 11 analysts covering the stock. Of those, 11 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for CSTL is $49.80, representing a +104.3% upside from the current price of $24.37. Price targets range from a low of $47.00 to a high of $52.00.
